Patient Advocate Says Novartis' $475 000 Breakthrough Should Cost Just $160 000 - (Forbes via NewsPoints Desk)

  • An analysis published in the journal Health Affairs suggests that Novartis' recently approved CAR-T therapy Kymriah is overpriced, Forbes reported Thursday.

  • In the study, the investigators used publicly available information to determine the correct price for the drug, concluding that it should carry a cost of $160 000, compared to its list price of $475 000.

  • "We're prepared to have Novartis come back and tell us the real numbers," commented study author David Mitchell, continuing "if this isn't right, tell us all the places these numbers aren't right."

  • Novartis spokesman Eric Althoff noted that while the drugmaker has not reviewed the study findings, the Institute for Clinical and Economic Review previously determined that Kymriah was cost-effective in children.

  • Althoff also argued that Mitchell and colleagues used incorrect assumptions in determining Novartis' manufacturing costs.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.